BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Buy” from Brokerages

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given an average recommendation of “Buy” by the seven analysts that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $29.43.

BLFS has been the topic of several research analyst reports. Benchmark restated a “buy” rating and issued a $30.00 price objective on shares of BioLife Solutions in a research report on Thursday, December 19th. Craig Hallum upped their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. TD Cowen upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, KeyCorp upped their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th.

Insider Buying and Selling at BioLife Solutions

In other news, CEO Greef Roderick De sold 46,896 shares of the stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total transaction of $1,098,773.28. Following the completion of the sale, the chief executive officer now owns 414,958 shares of the company’s stock, valued at approximately $9,722,465.94. This represents a 10.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Aby J. Mathew sold 7,604 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the sale, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. This trade represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 103,129 shares of company stock worth $2,344,018 over the last ninety days. Insiders own 2.20% of the company’s stock.

Institutional Trading of BioLife Solutions

A number of institutional investors have recently made changes to their positions in the stock. Harbour Capital Advisors LLC purchased a new stake in shares of BioLife Solutions during the fourth quarter valued at approximately $361,000. Principal Financial Group Inc. lifted its stake in BioLife Solutions by 4.7% in the third quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after acquiring an additional 8,580 shares during the period. Barclays PLC lifted its stake in BioLife Solutions by 20.1% in the third quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after acquiring an additional 10,803 shares during the period. Geode Capital Management LLC lifted its stake in BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares during the period. Finally, State Street Corp lifted its stake in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after acquiring an additional 95,788 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Trading Down 0.2 %

Shares of BioLife Solutions stock opened at $27.78 on Friday. BioLife Solutions has a 12-month low of $14.50 and a 12-month high of $28.88. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -26.21 and a beta of 1.92. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company’s 50-day moving average price is $26.42 and its 200-day moving average price is $24.77.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.